by The Francis Crick Institute Credit: Pixabay/CC0 Public Domain Monoclonal antibody therapies continue to neutralize SARS-CoV-2 variants currently in circulation, including omicron BA.4/5, according to laboratory findings from the Francis Crick Institute and the National Institute for Health Research (NIHR) UCLH Biomedical Research Center, published as a research letter in The Lancet. In the U.K., monoclonal antibodies are part of an important strategy to protect clinically...
UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS Researchers at the University of Colorado Anschutz Medical Campus have investigated how antiviral proteins called interferons interact with SARS-CoV-2, the cause of COVID-19. The study, published in Proceedings of the National Academy of Sciences USA, focuses on how the innate arm of the immune system defends against this coronavirus. The work resulted from...
By Suchandrima Bhowmik Jul 20 2022Reviewed by Aimee Molineux The emergence of the latest severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant, B.1.1.529 (Omicron) occurred in November 2021. Omicron was reported to contain over 30 mutations in the viral spike protein, the N-terminal domain (NTD), and the receptor binding domain (RBD). This led to increased transmissibility and evasion...
Depending on the variant, people may experience different long COVID symptoms, a study suggests. Jeffri Anthone Sapulette/EyeEm/Getty Images More than half of all people who recover from COVID-19 continue to experience lingering symptoms — known as ‘long COVID’ — 6 months later. A new observational study suggests that, compared with the original variant of SARS-CoV-2, the...
Share on Pinterest An antibody called S2E12 could inhibit several respiratory viruses. Sebastian Condrea/Getty Images Researchers have studied a dozen anti-SARS-CoV-2 antibodies isolated from people who had previously contracted the infection. They looked for antibodies that would not lose their effectiveness to new variants and that would work against a variety of respiratory viruses. They identified...
By Dr. Sanchari Sinha Dutta, Ph.D. Aug 12 2021 A team of scientists from Frankfurt, Germany, has recently explored the efficacy of vaccine- or infection-induced antibodies and therapeutic monoclonal antibodies in neutralizing kappa and delta variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The findings reveal that the delta variant is more resistant to...
PITTSBURGH – SARS-CoV-2 nanobodies—microscopic molecules developed at the University of Pittsburgh School of Medicine that neutralize the virus in animals—are remarkably active against mutations found in invariants, including Delta, according to new research by Pitt and Case Western Reserve University scientists. The findings, announced today in Nature Communications, describe three different mechanisms by which the...
by La Jolla Institute for Immunology T cells from people who have recovered from COVID-19 or received the Moderna or Pfizer-BioNTech vaccines are still able to recognize several concerning SARS-CoV-2 variants. Credit: La Jolla Institute for Immunology Researchers at La Jolla Institute for Immunology (LJI) have found that T cells from people who have recovered from...
By Sally Robertson, B.Sc. Jun 10 2021 Researchers in the UK and Austria have identified a novel class of antibodies that is highly effective at neutralizing the original strain of severe acute respiratory syndrome (SARS-CoV-2) and maintaining blocking activity against certain viral variants that have emerged. The SARS-CoV-2 virus is the agent responsible for the ongoing...
By Dr. Sanchari Sinha Dutta, Ph.D.Jun 8 2021 A team of scientists from the National Institutes of Health (NIH), USA, has recently identified six novel small molecule inhibitors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants. The study is currently available on the bioRxiv* preprint server. Study: A hybrid in silico approach reveals novel inhibitors of...
